Business
Endonovo Therapeutics Provides Corporate Update and 2016 Outlook
Endonovo Therapeutics Provides Corporate Update and 2016 Outlook.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\n \n \n Endonovo Therapeutics Provides Corporate Update and 2016 Outlook\n \n \nEndonovo Therapeutics Provides Corporate Update and 2016 Outlook\n\nEndonovo Focuses on Advancing Its Two Leading Platforms, Immunotronics and Cytotronics Into Clinical Trials\n\n \n LOS ANGELES, CA--(Marketwired - Mar 14, 2016) - Endonovo Therapeutics, Inc. (OTCQB: ENDV) (\"Endonovo\" or the \"Company\"), an innovative biotechnology company developing bioelectronics-based products and therapies for regenerative medicine, announced today a number of corporate developments.\n Endonovo Therapeutics recently repurchased $154,303 in convertible notes preventing additional shareholder dilution. \"We remain committed to preserving shareholder value while positioning the Company to attract institutional investors,\" stated CEO, Alan Collier. \"We intend to repay the remaining outstanding convertible notes over the coming months and commence our pre-clinical work on the liver.\"\n Endonovo's technology was previously shown to reduce acute inflammation in a Carrageenan Rat Footpad Edema (CFE) protocol, which is the drug/pharmaceutical industry gold standard for the initial screening of drugs and their effects on acute inflammation. \n \"We are now looking to evaluate the effectiveness of our technology in the treatment of acute inflammatory conditions in the liver, such as acute liver injury,\" stated Endonovo Chief Medical Officer Dr. Leonard Makowka M.D., PhD.\n Additionally, the Company has filed to withdraw its S-1 from registration of all the remaining shares under the Equity Purchase Agreement with Kodiak Capital, including 215,000 \"Commitment Shares\" issued to Kodiak Capital pursuant to the Equity Purchase Agreement.\n Furthermore, Endonovo has notified COR Clearing, LLC of its obligation to return to the Company a total of 1.89 million unpaid shares from the Equity Purchase Agreement with Kodiak Capital.\n \"We have an obligation to protect the interests of our shareholders as well as the Company's credibility and ensure no unscrupulous activity occurs with regard to our stock,\" stated Endonovo CEO, Alan Collier. \"We have been concerned about our stock activity for some time and believe removing these shares from the market may provide a solution and help ensure an efficient trading market for our stock.\"\n About Endonovo Therapeutics\n Endonovo...